Lund, Skane Oct 8, 2025 (Issuewire.com) - October 2025 Elixira, founded by inventor Tess Fries, today announces a major advancement in autonomous nanomedicine: an AI-guided nanobot platform engineered to function as an artificial immune system for lifelong cancer prevention.
While still in its development phase, Elixira builds on a foundation of validated scientific principles in nanotechnology, biomedical engineering, and AI. The invention outlines a feasible path toward a future where disease could be prevented before it forms not by replacing existing medicine, but by extending what is already possible.
Elixira is a next-generation, patent-pending, AI-guided nanobot platform designed as a one-time injection for lifelong, autonomous prevention across all cancer types. Its technical feasibility has been independently evaluated by a leading Contract Research Organization (CRO), and all core technologies forming its basis have been peer-reviewed and validated in prior research.
A comprehensive Feasibility White Paper further supports these findings, referencing more than one hundred peer-reviewed studies confirming the in vivo feasibility of Elixiras underlying nanomedical, bioengineering, and AI-based principles. The document is available to prospective partners under NDA.
Developed on in vivoproven nanotechnology and biomedical engineering principles, Elixira integrates self-sustaining energy systems and multiple elimination methods to enable a proactive, continuous prevention model. Operating autonomously inside the human body, it is designed to detect, target, and neutralize cancer cells in real time powered entirely by its own renewable energy systems.
Elixira represents the evolution of medicine we all deserve transforming cancer care from reactive treatment to proactive prevention with a sustainable business model that offers even more revenue to pharma and stakeholders than today, says Tess Fries. The goal is to eliminate disease by technological design, through intelligent nanotechnology that operates in harmony with the bodys natural biology. Already in 2020, peer-reviewed work demonstrated the cornerstones required to make Elixira a reality. Elixira simply connects already validated nanomedical and bioengineering principles. The breakthrough lies not in creating something new, but rather the unity of its parts. The massive achievements of AI and technological innovation of today have already shown us that anything is possible, and eliminating disease by design is not an exception.
Elixira's long-term goal is to make preventive healthcare more accessible, ethical, and globally scalable, while inviting collaboration from researchers, engineers, and industry leaders who share the belief that medicine can evolve from treatment to prevention in a way that increases long-term profitability and ensures a smooth, sustainable transition for all stakeholders.
This initiative also marks the foundation of a broader medical framework called Nanoism a scientific movement dedicated to evolving healthcare from treatment to continuous prevention through autonomous nanotechnology.
Elixira follows a licensing-based collaboration model, designed to allow collaborative development and ethical commercialization under license, without equity dilution. Elixira is now exploring strategic licensing partnerships with organizations in nanotechnology and oncology that share its vision of advancing prevention through science and compassion.
About Elixira
Elixira is a Sweden-based biotech initiative pioneering innovation and intellectual property in autonomous nanomedicine for lifelong cancer prevention. By merging nanotechnology with AI-driven adaptive intelligence, Elixira aims to create a future where disease can be prevented before symptoms arise starting with cancer.
Website: https://elixira.tech
Press contact: [email protected]
Source :Elixira
This article was originally published by IssueWire. Read the original article here.